dextroamphetamine has been researched along with Dementia Praecox in 118 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the safety and pharmacokinetics of lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, this double-blind study enrolled adults with clinically stable schizophrenia who were adherent (≥12 weeks) to antipsychotic pharmacotherapy." | 9.19 | Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ( Corcoran, M; Dirks, B; Ermer, J; Gertsik, L; Martin, P; Raychaudhuri, A; Stevenson, A; Walling, D, 2014) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 9.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "Kynurenic acid (KYNA) is an endogenous compound implicated in the pathophysiology of schizophrenia." | 7.75 | Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. ( Andersson, AS; Engberg, G; Erhardt, S; Holtze, M; Larsson, K; Linderholm, KR; Nilsson-Todd, LK; Olsson, E; Olsson, SK; Schwieler, L, 2009) |
| "Haloperidol and clozapine were tested in rats after daily administration for 3 and 21 days in combination with vehicle or PCP (2." | 5.30 | A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. ( Sams-Dodd, F, 1998) |
| "To assess the safety and pharmacokinetics of lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, this double-blind study enrolled adults with clinically stable schizophrenia who were adherent (≥12 weeks) to antipsychotic pharmacotherapy." | 5.19 | Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ( Corcoran, M; Dirks, B; Ermer, J; Gertsik, L; Martin, P; Raychaudhuri, A; Stevenson, A; Walling, D, 2014) |
| "Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0." | 5.07 | Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991) |
| "Methylphenidate hydrochloride dextroamphetamine sulfate, and levamfetamine succinate have potential as pharmacologic tools for the indirect evaluation of the role of neurotransmitters in schizophrenia." | 5.04 | Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. ( Davis, JM; Janowsky, DS, 1976) |
| " Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol." | 3.83 | Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. ( Cheng, J; Giguere, PM; Huang, XP; Kozikowski, AP; McCorvy, JD; Pogorelov, VM; Rodriguiz, RM; Roth, BL; Schmerberg, CM; Wetsel, WC; Zhu, H, 2016) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "Kynurenic acid (KYNA) is an endogenous compound implicated in the pathophysiology of schizophrenia." | 3.75 | Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. ( Andersson, AS; Engberg, G; Erhardt, S; Holtze, M; Larsson, K; Linderholm, KR; Nilsson-Todd, LK; Olsson, E; Olsson, SK; Schwieler, L, 2009) |
| " We studied the effect of SB-271046 [5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide], a specific 5-HT(6) receptor antagonist, in three models for the positive symptoms of schizophrenia---D-amphetamine-induced hyperactivity, and D-amphetamine- or phencyclidine (PCP)-disrupted prepulse inhibition (PPI)." | 3.71 | Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. ( Arnt, J; Didriksen, M; Pouzet, B, 2002) |
| " By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
| "Schizophrenia is a chronic severe mental disorder with a presumed neurodevelopmental origin, and no effective treatment." | 1.43 | Genetic blockade of adenosine A2A receptors induces cognitive impairments and anatomical changes related to psychotic symptoms in mice. ( Ciruela, F; Gracia-Rubio, I; Moscoso-Castro, M; Valverde, O, 2016) |
| "Schizophrenia is a complex dynamic disorder comprising a wide range of neurobiological alterations including dopaminergic dysfunction." | 1.38 | Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. ( Dehning, S; Karch, S; Koch, W; Möller, HJ; Müller, N; Poepperl, G; Pogarell, O; Tatsch, K, 2012) |
| "Schizophrenia is a debilitating psychotic disorder that affects up to 1." | 1.38 | Assessment of behaviors modeling aspects of schizophrenia in Csmd1 mutant mice. ( Distler, MG; Dulawa, SC; Opal, MD; Palmer, AA, 2012) |
| "Ziprasidone was tested as a positive control." | 1.33 | Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. ( Andersen, MP; Hogg, S; Pouzet, B, 2005) |
| "Haloperidol and clozapine were tested in rats after daily administration for 3 and 21 days in combination with vehicle or PCP (2." | 1.30 | A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. ( Sams-Dodd, F, 1998) |
| "The authors conducted a study in which schizophrenic-like behavioral disturbances were induced in members of a macaque social colony by the chronic administration of d-amphetamine." | 1.25 | A schizophreniform behavioral psychosis mediated by dopamine. ( Davis, JM; Garver, DL; Maas, JW; Schlemmer, RF, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 68 (57.63) | 18.7374 |
| 1990's | 16 (13.56) | 18.2507 |
| 2000's | 13 (11.02) | 29.6817 |
| 2010's | 20 (16.95) | 24.3611 |
| 2020's | 1 (0.85) | 2.80 |
| Authors | Studies |
|---|---|
| Wolinsky, TD | 1 |
| Swanson, CJ | 1 |
| Smith, KE | 1 |
| Zhong, H | 1 |
| Borowsky, B | 1 |
| Seeman, P | 2 |
| Branchek, T | 1 |
| Gerald, CP | 1 |
| Weinstein, JJ | 1 |
| van de Giessen, E | 1 |
| Rosengard, RJ | 1 |
| Xu, X | 1 |
| Ojeil, N | 1 |
| Brucato, G | 1 |
| Gil, RB | 1 |
| Kegeles, LS | 1 |
| Laruelle, M | 1 |
| Slifstein, M | 1 |
| Abi-Dargham, A | 1 |
| Openshaw, RL | 1 |
| Thomson, DM | 1 |
| Thompson, R | 1 |
| Penninger, JM | 1 |
| Pratt, JA | 1 |
| Morris, BJ | 1 |
| Dawson, N | 1 |
| Rogóż, Z | 1 |
| Kameda, SR | 1 |
| Fukushiro, DF | 1 |
| Wuo-Silva, R | 1 |
| Trombin, TF | 1 |
| Procópio-Souza, R | 1 |
| Brandão, LC | 1 |
| Sanday, L | 1 |
| Patti, CL | 1 |
| Mári-Kawamoto, E | 1 |
| Tufik, S | 1 |
| D'Almeida, V | 1 |
| Frussa-Filho, R | 1 |
| Lasser, RA | 1 |
| Dirks, B | 2 |
| Nasrallah, H | 1 |
| Kirsch, C | 1 |
| Gao, J | 1 |
| Pucci, ML | 1 |
| Knesevich, MA | 1 |
| Lindenmayer, JP | 1 |
| Hart, AB | 1 |
| Gamazon, ER | 1 |
| Engelhardt, BE | 1 |
| Sklar, P | 1 |
| Kähler, AK | 1 |
| Hultman, CM | 1 |
| Sullivan, PF | 1 |
| Neale, BM | 1 |
| Faraone, SV | 1 |
| de Wit, H | 1 |
| Cox, NJ | 1 |
| Palmer, AA | 2 |
| Martin, P | 1 |
| Gertsik, L | 1 |
| Walling, D | 1 |
| Stevenson, A | 1 |
| Corcoran, M | 1 |
| Raychaudhuri, A | 1 |
| Ermer, J | 1 |
| Cheng, J | 1 |
| Giguere, PM | 1 |
| Schmerberg, CM | 1 |
| Pogorelov, VM | 1 |
| Rodriguiz, RM | 1 |
| Huang, XP | 1 |
| Zhu, H | 1 |
| McCorvy, JD | 1 |
| Wetsel, WC | 1 |
| Roth, BL | 1 |
| Kozikowski, AP | 1 |
| Moscoso-Castro, M | 1 |
| Gracia-Rubio, I | 1 |
| Ciruela, F | 1 |
| Valverde, O | 1 |
| Olsson, SK | 1 |
| Andersson, AS | 1 |
| Linderholm, KR | 1 |
| Holtze, M | 1 |
| Nilsson-Todd, LK | 1 |
| Schwieler, L | 1 |
| Olsson, E | 1 |
| Larsson, K | 1 |
| Engberg, G | 1 |
| Erhardt, S | 1 |
| Li, M | 1 |
| He, W | 1 |
| Mead, A | 1 |
| Karl, T | 2 |
| Chesworth, R | 2 |
| Duffy, L | 2 |
| Herzog, H | 2 |
| Zhornitsky, S | 1 |
| Potvin, S | 1 |
| Stip, E | 1 |
| Rompré, PP | 1 |
| Albrecht, MA | 1 |
| Martin-Iverson, MT | 1 |
| Price, G | 1 |
| Lee, J | 1 |
| Iyyalol, R | 1 |
| Profaci, CP | 2 |
| Krolikowski, KA | 1 |
| Olszewski, RT | 2 |
| Neale, JH | 2 |
| Dean, OM | 1 |
| van den Buuse, M | 1 |
| Berk, M | 1 |
| Copolov, DL | 1 |
| Mavros, C | 1 |
| Bush, AI | 1 |
| Wierońska, JM | 1 |
| Stachowicz, K | 1 |
| Acher, F | 1 |
| Lech, T | 1 |
| Pilc, A | 1 |
| Pogarell, O | 1 |
| Koch, W | 1 |
| Karch, S | 1 |
| Dehning, S | 1 |
| Müller, N | 1 |
| Tatsch, K | 1 |
| Poepperl, G | 1 |
| Möller, HJ | 1 |
| Meyer, F | 1 |
| Louilot, A | 1 |
| Swerdlow, NR | 1 |
| Shilling, PD | 1 |
| Breier, M | 1 |
| Trim, RS | 1 |
| Light, GA | 2 |
| Marie, RS | 1 |
| Janczura, KJ | 1 |
| Ball, SR | 1 |
| Madore, JC | 1 |
| Lavin, KM | 1 |
| Lee, JC | 1 |
| Lee, MJ | 1 |
| Der, EK | 1 |
| Hark, TJ | 1 |
| Farago, PR | 1 |
| Bzdega, T | 1 |
| Distler, MG | 1 |
| Opal, MD | 1 |
| Dulawa, SC | 1 |
| Carnwath, T | 1 |
| Garvey, T | 1 |
| Holland, M | 1 |
| CASEY, JF | 1 |
| HOLLISTER, LE | 1 |
| KLETT, CJ | 1 |
| LASKY, JJ | 1 |
| CAFFEY, EM | 1 |
| SOURS, JA | 1 |
| LEHMANN, HE | 1 |
| BAN, TA | 1 |
| PROUT, CT | 1 |
| DAVISON, K | 1 |
| MODELL, W | 1 |
| HUSSAR, AE | 1 |
| Pouzet, B | 3 |
| Andersen, MP | 1 |
| Hogg, S | 1 |
| Tossell, JW | 1 |
| Greenstein, DK | 1 |
| Davidson, AL | 1 |
| Job, SB | 1 |
| Gochman, P | 1 |
| Lenane, M | 1 |
| Nugent Iii, TF | 1 |
| Gogtay, N | 1 |
| Sporn, AL | 1 |
| Rapoport, JL | 2 |
| Dunn, MJ | 1 |
| Killcross, S | 1 |
| Thomsen, M | 1 |
| Wörtwein, G | 1 |
| Fink-Jensen, A | 1 |
| Woldbye, DP | 1 |
| Wess, J | 1 |
| Caine, SB | 1 |
| Nudelman, A | 1 |
| Gil-Ad, I | 1 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 1 |
| Geffen, Y | 1 |
| Weizman, A | 1 |
| Rephaeli, A | 1 |
| van Kammen, DP | 14 |
| Docherty, JP | 9 |
| Marder, SR | 7 |
| Schulz, SC | 4 |
| Bunney, WE | 11 |
| Angrist, B | 6 |
| Rotrosen, J | 2 |
| Gershon, S | 3 |
| Kim, JS | 1 |
| Kornhuber, HH | 1 |
| Brand, U | 1 |
| Menge, HG | 1 |
| Haracz, JL | 1 |
| Pickar, D | 1 |
| Cohen, MR | 1 |
| Naber, D | 1 |
| Ellison, GD | 1 |
| Eison, MS | 1 |
| Sternberg, DE | 1 |
| Wray, SR | 1 |
| Melville, GN | 1 |
| Wenger, T | 1 |
| Louden, D | 1 |
| MacLennan, AJ | 1 |
| Maier, SF | 1 |
| Desai, NG | 1 |
| Gangadhar, BN | 1 |
| Pradhan, N | 1 |
| Channabasavanna, SM | 1 |
| Rayner, JN | 2 |
| Peselow, E | 1 |
| Rubinstein, M | 1 |
| Corwin, J | 1 |
| Ostow, M | 1 |
| Beninger, RJ | 1 |
| Hahn, BL | 1 |
| Zahn, TP | 1 |
| Thompson, CL | 1 |
| Dalton, L | 1 |
| Ebert, MH | 1 |
| Rosenblatt, JE | 3 |
| Antelman, SM | 1 |
| Eichler, AJ | 1 |
| Black, CA | 1 |
| Kocan, D | 1 |
| Solomon, PR | 1 |
| Crider, A | 1 |
| Winkelman, JW | 1 |
| Turi, A | 1 |
| Kamer, RM | 1 |
| Kaplan, LJ | 1 |
| Schiff, SR | 1 |
| Wolkin, A | 2 |
| Sanfilipo, M | 2 |
| Duncan, E | 1 |
| Wieland, S | 1 |
| Wolf, AP | 1 |
| Brodie, JD | 1 |
| Cooper, TB | 1 |
| Laska, E | 1 |
| Rotrosen, JP | 1 |
| Mittleman, G | 1 |
| LeDuc, PA | 1 |
| Whishaw, IQ | 1 |
| Lipska, BK | 1 |
| Jaskiw, GE | 1 |
| Weinberger, DR | 3 |
| Siegel, BV | 1 |
| Trestman, RL | 1 |
| O'Flaithbheartaigh, S | 1 |
| Mitropoulou, V | 1 |
| Amin, F | 1 |
| Kirrane, R | 1 |
| Silverman, J | 1 |
| Schmeidler, J | 1 |
| Keefe, RS | 1 |
| Siever, LJ | 1 |
| Weiner, I | 1 |
| Shadach, E | 1 |
| Tarrasch, R | 1 |
| Kidron, R | 1 |
| Feldon, J | 1 |
| Strakowski, SM | 1 |
| Sax, KW | 1 |
| Setters, MJ | 1 |
| Stanton, SP | 1 |
| Keck, PE | 1 |
| Sams-Dodd, F | 1 |
| Jentsch, JD | 1 |
| Taylor, JR | 1 |
| Roth, RH | 1 |
| El-Khodor, BF | 1 |
| Boksa, P | 1 |
| McKetin, R | 1 |
| Ward, PB | 2 |
| Catts, SV | 2 |
| Mattick, RP | 1 |
| Bell, JR | 1 |
| Kröner, S | 1 |
| Schall, U | 1 |
| Sticht, G | 1 |
| Banger, M | 1 |
| Haffner, HT | 1 |
| Malaspina, D | 1 |
| Geyer, MA | 1 |
| Luber, BM | 1 |
| Coleman, EA | 1 |
| Sackeim, HA | 1 |
| Braff, DL | 1 |
| Mattsson, A | 1 |
| Ogren, SO | 1 |
| Olson, L | 1 |
| Didriksen, M | 2 |
| Arnt, J | 2 |
| Malick, JB | 1 |
| Billingsley, ML | 1 |
| Kubena, RK | 1 |
| Goldstein, JM | 1 |
| Goode, DJ | 1 |
| Meltzer, HY | 2 |
| Mazura, TA | 1 |
| Garver, DL | 1 |
| Schlemmer, RF | 1 |
| Maas, JW | 1 |
| Davis, JM | 4 |
| Borison, RL | 3 |
| Diamond, BI | 3 |
| Gillin, JC | 2 |
| Lake, CR | 1 |
| Ziegler, MG | 1 |
| Havdala, HS | 2 |
| Siris, SG | 1 |
| Yehuda, S | 1 |
| Reches, A | 1 |
| Ebstein, RP | 1 |
| Belmaker, RH | 1 |
| Matejcek, M | 1 |
| Trulson, ME | 1 |
| Jacobs, BL | 1 |
| Janowsky, DS | 1 |
| Kornetsky, C | 1 |
| Markianos, ES | 1 |
| Nyström, I | 1 |
| Reichel, H | 1 |
| Matussek, N | 1 |
| Ullman, KC | 1 |
| Jimerson, DC | 1 |
| Post, RM | 1 |
| Siris, P | 1 |
| Ebert, M | 1 |
| Itil, TM | 2 |
| Herrmann, WM | 1 |
| Akpinar, S | 1 |
| Devis, D | 1 |
| Kong, D | 1 |
| Goldberg, TE | 2 |
| Bigelow, LB | 2 |
| Daniel, DG | 2 |
| Kleinman, JE | 2 |
| Jones, DW | 1 |
| Zigun, JR | 1 |
| Coppola, R | 1 |
| Handel, S | 1 |
| Berman, KF | 1 |
| Ellenbroek, BA | 1 |
| Willemen, AP | 1 |
| Cools, AR | 1 |
| Mathew, RJ | 1 |
| Wilson, WH | 1 |
| Pandurangi, AK | 1 |
| Goldberg, SC | 1 |
| Brink, DD | 1 |
| Hill, MH | 1 |
| Gulati, AN | 1 |
| Hamer, RM | 1 |
| Sommers, AA | 1 |
| Luchins, DJ | 1 |
| Boronow, JJ | 1 |
| Lipton, MA | 1 |
| Stevens, J | 1 |
| Wilson, K | 1 |
| Foote, W | 1 |
| Barker, ET | 1 |
| Mason, MH | 1 |
| Vogel, GW | 2 |
| Janowski, DS | 1 |
| El-Yousef, MK | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Snyder, SH | 1 |
| Aghajanian, GK | 1 |
| Matthysse, S | 1 |
| Saletu, B | 1 |
| Saletu, M | 1 |
| West, AP | 1 |
| Traub, AC | 1 |
| Rappaport, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter Study With Open-label & Randomized Double-blind Placebo-controlled Withdrawal Phases to Evaluate the Efficacy, Safety, & Tolerability of SPD489 in Adults With Schizophrenia & Predominant Negative Symptoms Who Are Clinically Stable &[NCT00922272] | Phase 2 | 92 participants (Actual) | Interventional | 2009-09-14 | Completed | ||
| Differences in Voxel-based Morphometry of Different Brain Structures in Patients With Mood Disorder Bipolar Mania in Comparison to Morphometry of Nrmal Controls[NCT03181698] | 45 participants (Actual) | Observational | 2017-09-22 | Completed | |||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Brain Changes in Pediatric Obstructive Sleep Apnea[NCT05368077] | 70 participants (Anticipated) | Interventional | 2022-05-14 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4 Double-blind Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Double-blind Phase) | 0.4 |
| Placebo (Double-blind Phase) | -2.9 |
BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4
| Intervention | correct numerals (Least Squares Mean) |
|---|---|
| SPD489 (Double-blind Phase) | 0.1 |
| Placebo (Double-blind Phase) | -2.7 |
HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and week 4 Double-blind Phase
| Intervention | words recalled (Least Squares Mean) |
|---|---|
| SPD489 (Double-blind Phase) | -1.5 |
| Placebo (Double-blind Phase) | 1.0 |
LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4
| Intervention | correct sequences (Least Squares Mean) |
|---|---|
| SPD489 (Double-blind Phase) | -0.1 |
| Placebo (Double-blind Phase) | 1.3 |
The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4 Double-blind Phase
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| SPD489 (Double-blind Phase) | 4.5 |
| Placebo (Double-blind Phase) | 2.2 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Open-label Phase) | -1.8 |
CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Open-label Phase) | -0.7 |
CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression. (NCT00922272)
Timeframe: Open-label Baseline and Week 4 of Double-blind Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Double-blind Phase) | -0.1 |
| Placebo (Double-blind Phase) | -0.7 |
HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test. (NCT00922272)
Timeframe: Open-label Baseline and Week 10
| Intervention | words recalled (Mean) |
|---|---|
| SPD489 (Open-label Phase) | 0.7 |
LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences. (NCT00922272)
Timeframe: Open-label Baseline and week 10 Open-label Phase
| Intervention | correct sequences (Mean) |
|---|---|
| SPD489 (Open-label Phase) | 0.8 |
The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Open-label Phase) | -12.9 |
PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Open-label Phase) | -0.7 |
PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality. (NCT00922272)
Timeframe: Open-label Baseline and Week 4 Double-blind Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Double-blind Phase) | 0.3 |
| Placebo (Double-blind Phase) | -1.7 |
SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment. (NCT00922272)
Timeframe: Open-label Baseline and Week 4 Double-blind Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Double-blind Phase) | 0.00 |
| Placebo (Double-blind Phase) | 0.00 |
SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| SPD489 (Open-label Phase) | -0.01 |
BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them. (NCT00922272)
Timeframe: Open-label Baseline and week 10 Open-label Phase
| Intervention | correct numerals (Mean) |
|---|---|
| SPD489 (Open-label Phase) | 2.3 |
Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Week 4 Double-blind Phase
| Intervention | Percent of participants (Number) |
|---|---|
| SPD489 (Double-blind Phase) | 71.4 |
| Placebo (Double-blind Phase) | 82.4 |
Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Week 10 Open-label Phase
| Intervention | Percent of participants (Number) |
|---|---|
| SPD489 (Open-label Phase) | 52.9 |
CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00922272)
Timeframe: Double-blind Phase Week 4
| Intervention | Percent of participants (Number) |
|---|---|
| SPD489 (Double-blind Phase) | 17.2 |
| Placebo (Double-blind Phase) | 27.6 |
CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00922272)
Timeframe: Open-label Phase Week 10
| Intervention | Percent of participants (Number) |
|---|---|
| SPD489 (Open-label Phase) | 30.0 |
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4 Double-blind Phase
| Intervention | T-scores (Least Squares Mean) | ||
|---|---|---|---|
| Global Executive Composite | Behavioral Recognition Index | Metacognition Index | |
| Placebo (Double-blind Phase) | -1.2 | -1.6 | -0.7 |
| SPD489 (Double-blind Phase) | -1.7 | -0.9 | -2.0 |
The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4 Double-blind Phase
| Intervention | Units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Positive subscale | Negative subscale | General Psychopathology subscale | |
| Placebo (Double-blind Phase) | -0.1 | -0.1 | -0.9 |
| SPD489 (Double-blind Phase) | 0.5 | 0.9 | 0.9 |
The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4 Double-blind Phase
| Intervention | Units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Affective Flattening | Alogia | Avolition-Apathy | Anhedonia-Asociality | Attention | |
| Placebo (Double-blind Phase) | 0.2 | 0.0 | 0.1 | 0.1 | 0.3 |
| SPD489 (Double-blind Phase) | 0.2 | 0.5 | 0.2 | 0.3 | 0.4 |
UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living. (NCT00922272)
Timeframe: Double-blind Randomization Baseline and Week 4 Double-blind Phase
| Intervention | Scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Total Skills | Communication Skills | Financial Skills | |
| Placebo (Double-blind Phase) | 0.0 | -0.6 | 0.9 |
| SPD489 (Double-blind Phase) | -1.5 | -1.5 | -0.3 |
BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness. (NCT00922272)
Timeframe: Open-label Baseline and week 10 Open-label Phase
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Objective | Subjective | Global | |
| SPD489 (Open-label Phase) | 0.0 | 0.0 | 0.0 |
BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness. (NCT00922272)
Timeframe: Open-label Baseline and Week 4 Double-blind Phase
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Objective | Subjective | Global | |
| Placebo (Double-blind Phase) | -0.1 | -0.1 | -0.2 |
| SPD489 (Double-blind Phase) | 0.0 | 0.0 | 0.0 |
BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | T-scores (Mean) | ||
|---|---|---|---|
| Global Executive Composite | Behavioral Recognition Index | Metacognition Index | |
| SPD489 (Open-label Phase) | -3.9 | -3.1 | -3.9 |
The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Positive subscale | Negative subscale | General Psychopathology subscale | |
| SPD489 (Open-label Phase) | -1.0 | -4.8 | -4.0 |
The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment. (NCT00922272)
Timeframe: Open-label Baseline and Week 10 Open-label Phase
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Affective Flattening | Alogia | Avolition-Apathy | Anhedonia-Asociality | Attention | |
| SPD489 (Open-label Phase) | -0.9 | -0.9 | -0.5 | -0.7 | -0.7 |
UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living. (NCT00922272)
Timeframe: Open-label Baseline and week 10 Open-label Phase
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Total Skills | Communication Skills | Financial Skills | |
| SPD489 (Open-label Phase) | 6.2 | 3.7 | 2.5 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00922272)
Timeframe: Double-blind Randomization Baseline
| Intervention | Percent of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Placebo (Double-blind Phase) | 0 | 2.9 | 60.0 | 37.1 | 0 | 0 | 0 |
| SPD489 (Double-blind Phase) | 0 | 2.9 | 50.0 | 38.2 | 8.8 | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00922272)
Timeframe: Week 10 Open-label Phase
| Intervention | Percent of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| SPD489 (Open-label Phase) | 0 | 2.9 | 54.3 | 38.6 | 4.3 | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00922272)
Timeframe: Week 4 Double-blind Phase
| Intervention | Percent of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Placebo (Double-blind Phase) | 0 | 13.8 | 69.0 | 13.8 | 3.4 | 0 | 0 |
| SPD489 (Double-blind Phase) | 0 | 3.4 | 34.5 | 48.3 | 13.8 | 0 | 0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00922272)
Timeframe: Open-label Baseline
| Intervention | Percent of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| SPD489 (Open-label Phase) | 0 | 0 | 29.3 | 55.4 | 14.1 | 1.1 | 0 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
4 reviews available for dextroamphetamine and Dementia Praecox
| Article | Year |
|---|---|
NARCOLEPSY AND OTHER DISTURBANCES IN THE SLEEP-WAKING RHYTHM: A STUDY OF 115 CASES WITH REVIEW OF THE LITERATURE.
Topics: Black People; Cataplexy; Craniocerebral Trauma; Depression; Dextroamphetamine; Encephalitis; Halluci | 1963 |
Biologic tests in psychiatry.
Topics: Anxiety Disorders; Apomorphine; Clonidine; Dexamethasone; Dextroamphetamine; Growth Hormone; Humans; | 1984 |
The effects of D-amphetamine on dopaminergic regulated mechanisms of physiological and behavioral thermoregulation.
Topics: Animals; Autonomic Nervous System; Behavior, Animal; Body Temperature Regulation; Dextroamphetamine; | 1979 |
REM deprivation. 3. Dreaming and psychosis.
Topics: Anxiety; Behavior; Depression; Dextroamphetamine; Dreams; Drive; Eye Movements; Hallucinations; Huma | 1968 |
26 trials available for dextroamphetamine and Dementia Praecox
| Article | Year |
|---|---|
Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.
Topics: Adult; Antipsychotic Agents; Dextroamphetamine; Dopamine Agonists; Double-Blind Method; Drug Adminis | 2013 |
Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Topics: Adult; Cross-Over Studies; Dextroamphetamine; Dose-Response Relationship, Drug; Double-Blind Method; | 2014 |
Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.
Topics: Adolescent; Adult; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Dextroamphetamine; Dopa | 1980 |
Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients.
Topics: Adult; beta-Endorphin; Dextroamphetamine; Endorphins; Female; Growth Hormone; Humans; Male; Prolacti | 1982 |
Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.
Topics: Adolescent; Adult; Dextroamphetamine; Dopamine; Euphoria; Female; Humans; Long-Term Care; Male; Midd | 1982 |
Pimozide blocks establishment but not expression of amphetamine-produced environment-specific conditioning.
Topics: Animals; Conditioning, Psychological; Dextroamphetamine; Humans; Male; Pimozide; Rats; Rats, Inbred | 1983 |
Autonomic effects of dextroamphetamine in normal men: implications for hyperactivity and schizophrenia.
Topics: Adult; Autonomic Nervous System; Child; Dextroamphetamine; Galvanic Skin Response; Heart Rate; Human | 1981 |
Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response.
Topics: Adolescent; Adult; Dextroamphetamine; Double-Blind Method; Female; Humans; Male; Middle Aged; Pimozi | 1982 |
Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology.
Topics: Arousal; Blood Glucose; Cerebral Cortex; Dextroamphetamine; Dominance, Cerebral; Double-Blind Method | 1994 |
D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder.
Topics: Adult; Aged; Arousal; Attention; Cognition Disorders; Dextroamphetamine; Dopamine; Dopamine Agents; | 1996 |
Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans.
Topics: Adult; Arousal; Bipolar Disorder; Blinking; Central Nervous System Stimulants; Dextroamphetamine; Do | 1997 |
Changes in auditory selective attention and event-related potentials following oral administration of D-amphetamine in humans.
Topics: Administration, Oral; Adult; Affect; Attention; Blood Pressure; Central Nervous System Stimulants; D | 1999 |
Effects of prepulses and d-amphetamine on performance and event-related potential measures on an auditory discrimination task.
Topics: Acoustic Stimulation; Adult; Dextroamphetamine; Discrimination Learning; Dopamine; Double-Blind Meth | 1999 |
Amphetamine disrupts P50 suppression in normal subjects.
Topics: Adrenergic Agents; Adult; Arousal; Attention; Central Nervous System Stimulants; Cerebral Cortex; De | 1999 |
Pimozide attentuates d-amphetamine-induced sleep changes in man.
Topics: Adult; Dextroamphetamine; Humans; Pimozide; Schizophrenia; Sleep; Sleep, REM | 1978 |
d-Amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment.
Topics: Clinical Trials as Topic; Dextroamphetamine; Double-Blind Method; Humans; Lithium; Pimozide; Prolact | 1978 |
Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.
Topics: Acute Disease; Amphetamines; Clinical Trials as Topic; Dextroamphetamine; Humans; Levodopa; Methylph | 1976 |
Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine.
Topics: Adult; Behavior; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dextroamphetamine; Dopam | 1976 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
Topics: Adult; Affect; Blinking; Cerebral Ventricles; Chronic Disease; Cognition; Concept Formation; Dextroa | 1991 |
The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia.
Topics: Adult; Cerebrovascular Circulation; Cognition; Dextroamphetamine; Female; Frontal Lobe; Haloperidol; | 1991 |
Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients.
Topics: Adult; Cerebrovascular Circulation; Dextroamphetamine; Female; Humans; Male; Mental Processes; Schiz | 1989 |
Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia.
Topics: Adult; Cerebral Ventricles; Clinical Trials as Topic; Dextroamphetamine; Double-Blind Method; Female | 1989 |
The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
Topics: Alprazolam; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Dextroamphetamine; Dose | 1986 |
Dextro-amphetamine diminishes negative symptoms in schizophrenia.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depression; Dextroamphetamine; Double-Blind Method; Emo | 1988 |
Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Dextroamphetamine; Euphoria; Female; Humans; Lithium; Male; | 1985 |
88 other studies available for dextroamphetamine and Dementia Praecox
| Article | Year |
|---|---|
The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia.
Topics: Amphetamine; Animals; Anxiety; Behavior, Animal; Catecholamines; Central Nervous System Stimulants; | 2007 |
PET imaging of dopamine-D2 receptor internalization in schizophrenia.
Topics: Adult; Amphetamine; Carbon Radioisotopes; Case-Control Studies; Central Nervous System Stimulants; D | 2018 |
Map2k7 Haploinsufficiency Induces Brain Imaging Endophenotypes and Behavioral Phenotypes Relevant to Schizophrenia.
Topics: Animals; Behavior, Animal; Brain; Connectome; Dextroamphetamine; Disease Models, Animal; Dopamine Up | 2020 |
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
Opposite effects of neonatal hypoxia on acute amphetamine-induced hyperlocomotion in adult and adolescent mice.
Topics: Age Factors; Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Hyperkinesis; Hyp | 2013 |
Genetic variation associated with euphorigenic effects of d-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Dextroamphetamine; Euphoria; Geneti | 2014 |
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
Topics: Animals; Brain; Catalepsy; Central Nervous System Stimulants; Cognition; Dextroamphetamine; Drug Des | 2016 |
Genetic blockade of adenosine A2A receptors induces cognitive impairments and anatomical changes related to psychotic symptoms in mice.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Dextroamphetamine; Disease | 2016 |
Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia.
Topics: Animals; Brain Chemistry; Data Interpretation, Statistical; Dextroamphetamine; Dopamine; Dopamine Up | 2009 |
Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine | 2009 |
Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Conditioning, | 2009 |
Schizophrenia-relevant behaviours in a genetic mouse model for Y2 deficiency.
Topics: Animals; Behavior, Animal; Cognition; Dextroamphetamine; Disease Models, Animal; Dizocilpine Maleate | 2010 |
Acoustic startle response and sensorimotor gating in a genetic mouse model for the Y1 receptor.
Topics: Animals; Dextroamphetamine; Disease Models, Animal; Dizocilpine Maleate; Humans; Male; Mice; Mice, K | 2010 |
Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine.
Topics: Amphetamine-Related Disorders; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous Syst | 2010 |
Dexamphetamine-induced reduction of P3a and P3b in healthy participants.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Dextroamphetamine; | 2011 |
Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.
Topics: Animals; Bridged Bicyclo Compounds; Dextroamphetamine; Disease Models, Animal; Dose-Response Relatio | 2011 |
N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder.
Topics: Acetylcysteine; Animals; Bipolar Disorder; Brain; Corpus Striatum; Cyclohexanones; Dextroamphetamine | 2011 |
Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.
Topics: Aminobutyrates; Amphetamines; Animals; Antipsychotic Agents; Benzhydryl Compounds; Dextroamphetamine | 2012 |
Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms.
Topics: Adolescent; Adult; Benzamides; Central Nervous System Stimulants; Dextroamphetamine; Diagnostic and | 2012 |
Early prefrontal functional blockade in rats results in schizophrenia-related anomalies in behavior and dopamine.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhi | 2012 |
Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats.
Topics: Animals; Behavior, Animal; Casein Kinase 1 epsilon; Catechol O-Methyltransferase; Dextroamphetamine; | 2012 |
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose | 2012 |
Assessment of behaviors modeling aspects of schizophrenia in Csmd1 mutant mice.
Topics: Alleles; Animals; Behavior, Animal; Dextroamphetamine; Disease Models, Animal; Exons; Female; Food P | 2012 |
The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence.
Topics: Adult; Amphetamine-Related Disorders; Antipsychotic Agents; Central Nervous System Stimulants; Dextr | 2002 |
Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipiramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine.
Topics: Chlorpromazine; Dextroamphetamine; Drug Therapy, Combination; Isocarboxazid; Psychopharmacology; Sch | 1961 |
NOTES FROM THE LOG-BOOK OF A PSYCHOPHARMACOLOGICAL RESEARCH UNIT. II.
Topics: Antidepressive Agents; Books; Dextroamphetamine; Diazepam; Geriatrics; Humans; Mental Disorders; Met | 1964 |
REACTIONS TO USE OF AMPHETAMINES AS OBSERVED IN A PSYCHIATRIC HOSPITAL.
Topics: Alcoholism; Amobarbital; Amphetamine; Amphetamines; Barbiturates; Dextroamphetamine; Hospitals, Psyc | 1964 |
EPISODIC DEPERSONALIZATION; OBSERVATIONS ON 7 PATIENTS.
Topics: Alcoholic Beverages; Amitriptyline; Amobarbital; Cochlea; Convulsive Therapy; Depersonalization; Dep | 1964 |
FAILURE OF DEXTROAMPHETAMINE SULFATE TO INFLUENCE EATING AND SLEEPING PATTERNS IN OBESE SCHIZOPHRENIC PATIENTS: CLINICAL AND PHARMACOLOGICAL SIGNIFICANCE.
Topics: Appetite; Blood Pressure; Dextroamphetamine; Drug Therapy; Eating; Heart Rate; Humans; Obesity; Puls | 1965 |
Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Bupropion; Cital | 2005 |
Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Medial prefrontal cortex infusion of alpha-flupenthixol attenuates systemic d-amphetamine-induced disruption of conditional discrimination performance in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Op | 2007 |
Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cocaine; Dextroamphetamine; Dopamine Ago | 2007 |
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Dextroamphetamine; Dopamine; Female; Haloperidol; Humans; Male; | 1980 |
Effects of chronic amphetamine treatment on the glutamate concentration in cerebrospinal fluid and brain: implications for a theory of schizophrenia.
Topics: Animals; Brain; Cerebral Cortex; Corpus Striatum; Dextroamphetamine; gamma-Aminobutyric Acid; Glutam | 1981 |
Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients.
Topics: Acute Disease; Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Dextroamphet | 1981 |
The dopamine hypothesis: an overview of studies with schizophrenic patients.
Topics: Adenylyl Cyclases; Brain; Catechol O-Methyltransferase; Dextroamphetamine; Dopa Decarboxylase; Dopam | 1982 |
Continuous amphetamine intoxication: an animal model of the acute psychotic episode.
Topics: Animals; Behavior, Animal; Caudate Nucleus; Dextroamphetamine; Disease Models, Animal; Dopamine; Hal | 1983 |
Interaction of dopamine agonists with disrupted mesolimbic pathways implications for mental health.
Topics: Animals; Apomorphine; Dextroamphetamine; Dopamine Antagonists; Humans; Male; Motor Activity; Nucleus | 1984 |
Coping and the stress-induced potentiation of stimulant stereotypy in the rat.
Topics: Animals; Cocaine; Dextroamphetamine; Disease Models, Animal; Drug Synergism; Humans; Rats; Schizophr | 1983 |
Treatment of negative schizophrenia with d-amphetamine.
Topics: Adult; Dextroamphetamine; Humans; Male; Schizophrenia; Schizophrenic Psychology | 1984 |
Partial improvement in negative schizophrenic symptoms after amphetamine.
Topics: Adult; Dextroamphetamine; Humans; Middle Aged; Schizophrenia; Schizophrenic Psychology | 1982 |
Dextro-amphetamine and schizophrenia.
Topics: Antidepressive Agents; Dextroamphetamine; Drug Therapy, Combination; Humans; Schizophrenia; Tranquil | 1983 |
Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.
Topics: Acute Disease; Adolescent; Adult; Dextroamphetamine; Dopamine; Female; Humans; Male; Middle Aged; Pi | 1982 |
d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.
Topics: Adolescent; Adult; Dextroamphetamine; Double-Blind Method; Female; Humans; Infusions, Parenteral; Ma | 1982 |
Interchangeability of stress and amphetamine in sensitization.
Topics: Animals; Behavior, Animal; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; Haloperido | 1980 |
Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder.
Topics: Animals; Attention; Avoidance Learning; Chlorpromazine; Dextroamphetamine; Dopamine; Dose-Response R | 1981 |
Conditioned dopaminergic activity.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Conditioning, Classical; Cues; Dextroamphet | 1982 |
The role of D1 and D2 receptors in the heightened locomotion induced by direct and indirect dopamine agonists in rats with hippocampal damage: an animal analogue of schizophrenia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Arousal; Brain Map | 1993 |
Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.
Topics: Animals; Animals, Newborn; Dextroamphetamine; Disease Models, Animal; Female; Haloperidol; Hippocamp | 1993 |
The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine.
Topics: Animals; Antipsychotic Agents; Association Learning; Attention; Clozapine; Conditioning, Classical; | 1996 |
A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Dextroamphetamine; Disease Models, Anima | 1998 |
Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Dextroamphetamine; Disease Mod | 1998 |
Birth insult increases amphetamine-induced behavioral responses in the adult rat.
Topics: Animals; Behavior, Animal; Birth Injuries; Cesarean Section; Dextroamphetamine; Disease Models, Anim | 1998 |
Facilitation of dopamine-mediated locomotor activity in adult rats following cholinergic denervation.
Topics: Aging; Animals; Apomorphine; Behavior, Animal; Cerebellum; Cerebral Cortex; Cholinergic Fibers; Dene | 2002 |
Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia.
Topics: Animals; Catalepsy; Central Nervous System Stimulants; Clozapine; Dextroamphetamine; Dose-Response R | 2002 |
Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.
Topics: Animals; Antipsychotic Agents; Catalepsy; Central Nervous System Stimulants; Dextroamphetamine; Dose | 2002 |
Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Clozapine; Conditioning, Operant; De | 1977 |
Hoffmann reflex abnormalities in psychotic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chronic Disease; Dextr | 1979 |
A schizophreniform behavioral psychosis mediated by dopamine.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Macaca; Receptors, Dopamin | 1975 |
A new animal model for schizophrenia: interactions with adrenergic mechanisms.
Topics: Animals; Behavior, Animal; Dextroamphetamine; Disease Models, Animal; Ditiocarb; Drug Antagonism; Dr | 1978 |
Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.
Topics: Adolescent; Adult; Blood Pressure; Dextroamphetamine; Dopamine beta-Hydroxylase; Drug Interactions; | 1979 |
A new animal model for schizophrenia: cholinergic and serotonergic modulation.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Dextroamphetamine; Disease Models, Animal; Dose-Resp | 1978 |
d-amphetamine inhibition of platelet MAO from schizophrenic patients.
Topics: Adult; Aged; Animals; Blood Platelets; Chronic Disease; Dextroamphetamine; Female; Haplorhini; Human | 1977 |
Pharmaco-electroencephalography: the value of quantified EEG in psychopharmacology.
Topics: Arousal; Dextroamphetamine; Electroencephalography; Humans; Psychopharmacology; Schizophrenia; Time | 1979 |
Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia?
Topics: Animals; Behavior; Dextroamphetamine; Disease Models, Animal; Haloperidol; Humans; Male; Phenethylam | 1977 |
Long-term amphetamine treatment decreases brain serotonin metabolism: implications for theories of schizophrenia.
Topics: Animals; Behavior, Animal; Brain; Brain Chemistry; Cats; Dextroamphetamine; Disease Models, Animal; | 1979 |
Serum dopamine-beta-hydroxylase in psychiatric patients and normals. Effect of d-amphetamine and haloperidol.
Topics: Depression; Dextroamphetamine; Dopamine beta-Hydroxylase; Haloperidol; Humans; Mental Disorders; Sch | 1976 |
Narcolepsy and schizophrenia.
Topics: Amitriptyline; Dextroamphetamine; Humans; Male; Middle Aged; Narcolepsy; Schizophrenia | 1977 |
Amphetamine-induced catecholamine activation in schizophrenia and depression: behavioral and physiological effects.
Topics: Behavior; Catecholamines; Depression; Dextroamphetamine; Double-Blind Method; Hemodynamics; Humans; | 1977 |
Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects.
Topics: Amphetamine; Dextroamphetamine; Dopamine; Humans; Levodopa; Male; Paranoid Disorders; Piribedil; Psy | 1977 |
[Release of dopamine and symptoms of schizophrenia].
Topics: Amphetamine; Dextroamphetamine; Dopamine; Humans; Methylphenidate; Norepinephrine; Schizophrenia | 1975 |
[Preliminary study of changes in plasma prostaglandin E1 in rats with experimental "schizophrenia"].
Topics: Alprostadil; Animals; Chlorpromazine; Dextroamphetamine; Disease Models, Animal; Female; Male; Rats; | 1992 |
Amphetamine response and duration of illness in schizophrenia.
Topics: Adult; Aged; Dextroamphetamine; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neurocognit | 1991 |
Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys.
Topics: Animals; Antipsychotic Agents; Benzazepines; Dextroamphetamine; Female; Humans; Macaca fascicularis; | 1989 |
d-Amphetamine raises cortisol levels in schizophrenic patients with and without chronic naltrexone pretreatment.
Topics: Adult; Circadian Rhythm; Dextroamphetamine; Female; Humans; Hydrocortisone; Male; Naltrexone; Premed | 1985 |
Neuropsychopharmacology of monoamines and their regulatory enzymes.
Topics: 5-Hydroxytryptophan; Amphetamine; Animals; Apomorphine; Biogenic Amines; Brain; Cocaine; Dextroamphe | 1974 |
GABA blockade, dopamine and schizophrenia: experimental studies in the cat.
Topics: Alkaloids; Aminobutyrates; Amitriptyline; Animals; Atropine; Behavior, Animal; Cats; Dextroamphetami | 1974 |
Bubber behind bars.
Topics: Amobarbital; Antisocial Personality Disorder; Attitude to Health; Audiovisual Aids; Communication; D | 1968 |
Proceedings: Effect of intravenous d-amphetamine, 1-amphetamine and methylphenidate in schizophrenics.
Topics: Amphetamine; Behavior; Dextroamphetamine; Hemodynamics; Humans; Methylphenidate; Psychiatric Status | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
A two factor theory of schizophrenia.
Topics: Acetylcholine; Amphetamine; Animals; Bipolar Disorder; Brain; Dextroamphetamine; Dopamine; Dose-Resp | 1974 |
Prospects for research on schizophrenia. V. Pharmacological observations, Drug-induced psychoses.
Topics: Animals; Brain; Brain Chemistry; Chlorpromazine; Dextroamphetamine; Dopamine; Humans; Limbic System; | 1972 |
The relationships between psychopathology and evoked responses before, during, and after psychotropic drug treatment.
Topics: Acoustic Stimulation; Adult; Auditory Perception; Child Behavior Disorders; Dextroamphetamine; Evoke | 1973 |
Interaction of low-dose amphetamine use with schizophrenia in outpatients: three case reports.
Topics: Acute Disease; Adult; Ambulatory Care; Amphetamine; Dextroamphetamine; Dose-Response Relationship, D | 1974 |
REM deprivation. I. The effect on schizophrenic patients.
Topics: Adaptation, Physiological; Adult; Dextroamphetamine; Dreams; Electroencephalography; Eye Movements; | 1968 |
Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background.
Topics: Acute Disease; Adult; Attention; Auditory Perception; Chlorpromazine; Chronic Disease; Dextroampheta | 1968 |